文献速递核素与放射性配体治疗放射性药物与辐射防护

177Lu-DOTATATE 肽受体放射性核素治疗在慢性肾脏病神经内分泌肿瘤患者中的安全性

Safety of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients with Chronic Kidney Disease.
PubMed 文献 · J Nucl Med · 2022-02-24

单中心回顾性分析33例估算肾小球滤过率低于60 mL/min/1.73 m²的神经内分泌肿瘤患者接受177Lu-DOTATATE治疗,其中26例为慢性肾脏病3a期、7例为3b期。永久性3或4级肾毒性发生率为3%,平均年eGFR下降估计为2.5%,未发现肾脏危险因素与肾功能永久下降之间的显著关系。作者认为该治疗在既存慢性肾脏病3期患者中似乎总体耐受良好,且多数患者报告生活质量改善。

要点

  • 33例eGFR低于60 mL/min/1.73 m²患者接受177Lu-DOTATATE,永久性3或4级肾毒性发生率为3%。
  • 平均年eGFR下降估计为2.5%,45%患者(n=15)记录到任何级别的eGFR永久下降小于10%。
  • 9例患者进入更高CKD分期:8例从3a期进入3b期,1例从3b期进入5期。

核心结论

  • 177Lu-DOTATATE在既存慢性肾脏病3期患者中似乎总体耐受良好,永久性主要肾毒性发生率低。
  • 177Lu-DOTATATE似乎具有良好的治疗效果,多数患者报告生活质量改善。

研究设计与样本

  • 单中心回顾性分析,纳入33例估算肾小球滤过率低于60 mL/min/1.73 m²的神经内分泌肿瘤患者。
  • 其中26例为慢性肾脏病3a期(eGFR 45-60 mL/min/1.73 m²),7例为慢性肾脏病3b期(eGFR 30-45 mL/min/1.73 m²)。
  • 记录肾毒性和eGFR随时间的变化,评估潜在危险因素与任何肾功能恶化(eGFR下降大于10%)之间的关联,并收集生存、影像学反应评估和生活质量数据。

主要发现

  • 永久性3或4级肾毒性发生率为3%(1例患者为4级肾毒性)。
  • 平均年eGFR下降估计为2.5%。
  • 45%患者(n=15)记录到任何级别的eGFR永久下降小于10%。
  • 9例患者进入更高慢性肾脏病分期:8例从3a期进入3b期,1例从3b期进入5期。
  • 未发现肾脏危险因素与肾功能永久下降之间的显著关系。

关键数值与推荐

  • 3或4级骨髓毒性发生率为9%。
  • 估计中位无进展生存期为42个月,中位总生存期为47个月。
  • 治疗结束时影像学评估显示部分缓解33%、疾病稳定55%、疾病进展12%。
  • 总体生活质量和内分泌评分(欧洲癌症研究与治疗组织生活质量问卷-胃肠神经内分泌肿瘤21)均有改善(P=0.046和P=0.041)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our purpose was to assess the efficacy and safety of 177Lu-DOTATATE in neuroendocrine tumor patients with reduced renal function. Methods: A single-center retrospective analysis was performed on 33 patients with an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m2 Of these, 26 had chronic kidney disease (CKD) stage 3a (eGFR, 45-60 mL/min/1.73 m2) and 7 had CKD 3b (eGFR, 30-45 mL/min/1.73 m2). Renal toxicity and temporal changes in eGFR were recorded. The association between potential risk factors and any kidney function deterioration (>10% reduction in eGFR) was evaluated. Data on survival, the radiologic response assessment, and quality of life were collected. Results: The incidence of permanent grade 3 or 4 nephrotoxicity was 3% (a single patient with grade 4 nephrotoxicity). The mean annual reduction in eGFR was estimated at 2.5%. A permanent decline of less than 10% in eGFR of any grade was recorded in 45% of patients (n = 15). Nine patients moved into higher CKD categories (8 patients who moved from CKD 3a to CKD 3b and 1 patient who moved from CKD 3b to CKD 5). No significant relationship was found between renal risk factors and a permanent reduction in renal function. Grade 3 or 4 bone marrow toxicity was observed in 9% of patients. The estimated median progression-free survival was 42 mo, and the median overall survival was 47 mo. At the end of treatment, the radiologic assessment showed a partial response in 33%, stable disease in 55%, and progressive disease in 12%. There was an improvement in global quality of life and endocrine score (European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-Gastrointestinal NET-21) (P = 0.046 and 0.041, respectively). Conclusion: 177Lu-DOTATATE appears to be generally well tolerated in patients with preexisting CKD 3, with a low incidence of permanent major nephrotoxicity. 177Lu-DOTATATE appears to have a good therapeutic effect, with most patients reporting improvement in quality of life.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Alsadik S, Gnanasegaran G, Chen L, et al. Safety of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients with Chronic Kidney Disease. J Nucl Med. 2022. PMID: 35210299. doi:10.2967/jnumed.121.263056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。